Oncozyme becomes Verlyx,
focusing on the treatment of liver disease.

Learn More >

oncozyme-verlyx

Verlyx Pharma presents data
on a novel oral form of pentamidine
(VLX103) at the AASLD
2014 annual meeting.

Learn More >

OE_SiteWeb_BulleImage_AASLDmeeting

VLX103 can deliver therapeutically relevant concentrations of pentamidine
to the liver, while avoiding
IV-related dose-limiting toxicity.

Learn More >

OE_SiteWeb_BulleImage_Hommebleu